Scott Samuelson, MD
Medical Oncology · Salt Lake City, UTNPI 1922288588
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Pfizer at 25.3% of the total. 2025 is the largest year on record at $553, 3.9 times the $141 reported in 2019. That places this record below the midpoint for medical oncology clinicians in UT, where the typical reported total is $2,800.
Across 75 payments — averaging $22.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$428
- Beigene USA, Inc.$116
- Rigel Pharmaceuticals, Inc.$111
- GSK$96
- Bayer$86
- Medtronic$84
- plus $770 from 20 others
What the payments were for
- Food & beverage$1,68199%
- Education$101%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 28 | $428 |
| Beigene USA, Inc. | 4 | $116 |
| Rigel Pharmaceuticals, Inc. | 1 | $111 |
| GSK | 6 | $96 |
| Bayer | 3 | $86 |
| Medtronic | 1 | $84 |
| AstraZeneca | 3 | $78 |
| Johnson & Johnson | 2 | $68 |
| EMD Serono, Inc. | 2 | $64 |
| Daiichi Sankyo Inc. | 3 | $63 |
| Array Biopharma Inc | 3 | $61 |
| Foundation Medicine, Inc. | 1 | $51 |
| Astellas Pharma US Inc | 3 | $50 |
| Genmab U.S., Inc. | 2 | $49 |
| Novartis | 2 | $45 |
| Taiho Oncology, Inc. | 1 | $43 |
| Bristol Myers Squibb | 1 | $31 |
| Amgen | 1 | $27 |
| Immunogen, Inc. | 1 | $25 |
| AbbVie | 1 | $22 |
| Puma Biotechnology, Inc. | 1 | $19 |
| Seagen Inc. | 1 | $18 |
| Exelixis Inc. | 1 | $17 |
| Sanofi | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Clovis Oncology, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tavalisse$111
How this compares
$1,691 in reported general payments places this provider in the 35th percentile of 43 medical oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 24 | $585,550 |
| ImbruvicaIbrutinib | 37 | $549,714 |
| RevlimidLenalidomide | 17 | $415,024 |
| XtandiEnzalutamide | 28 | $341,998 |
| IbrancePalbociclib | 20 | $306,753 |
| VenclextaVenetoclax | 24 | $239,162 |
| JakafiRuxolitinib Phosphate | 12 | $210,876 |
| ErleadaApalutamide | 15 | $205,029 |
| TagrissoOsimertinib Mesylate | 13 | $194,155 |
| CalquenceAcalabrutinib Maleate | 11 | $169,903 |
| Abiraterone Acetate | 129 | $117,740 |
| OrgovyxRelugolix | 14 | $36,872 |
| Tamoxifen Citrate | 18 | $1,014 |
| Hydroxyurea | 33 | $803 |
| Prednisone | 151 | $704 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $17 | $585,55024 claims |
| Bristol Myers SquibbRevlimid | $31 | $415,02417 claims |
| AstraZenecaTagrisso, Calquence | $78 | $364,05824 claims |
| Astellas Pharma US IncXtandi | $50 | $341,99828 claims |
| PfizerIbrance | $428 | $306,75320 claims |
| AbbVieVenclexta | $22 | $239,16224 claims |
| Johnson & JohnsonErleada | $68 | $205,02915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 43 medical oncology providers in Utah.
Other medical oncology in Salt Lake City
- Bradley HunterSalt Lake City$263K
- Robert HavardSalt Lake City$57K
- Wallace AkerleySalt Lake City$38K
- Ignacio Garrido-LagunaSalt Lake City$35K
- Mei WeiSalt Lake City$34K
- Xylina GreggSalt Lake City$31K
- Paul ShamiSalt Lake City$28K
- Nitin ChandramouliSalt Lake City$19K
- Kenneth GrossmannSalt Lake City$15K
- Manish KohliSalt Lake City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.